Resistance to BH3 mimetic S1 in SCLC cells that up‐regulate and phosphorylate Bcl‐2 through ERK1/2
Authors:
Open Access
- 8 May 2013
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 169 (7) , 1612-1623
Abstract
Background and Purpose: B cell lymphoma 2 (Bcl‐2) is a central regulator of cell survival that is overexpressed in the majority of small‐cell lung cancers (SCLC) and contributes to both malignant transformation and therapeutic resistance. The purpose of this work was to study the key factors that determine the sensitivity of SCLC cells to Bcl‐2 homology domain‐3 (BH3) mimetic S1 and the mechanism underlying the resistance of BH3 mimetics.Experimental Approaches: Western blot was used to evaluate the contribution of Bcl‐2 family members to the cellular response of SCLC cell lines to S1. Acquired resistant cells were derived from initially sensitive H1688 cells. Quantitative PCR and gene silencing were performed to investigate Bcl‐2 up‐regulation.Key Results: A progressive increase in the relative levels of Bcl‐2 and phosphorylated Bcl‐2 (pBcl‐2) characterized the increased de novo and acquired resistance of SCLC cell lines. Furthermore, acute treatment of S1 induced Bcl‐2 expression and phosphorylation. We showed that BH3 mimetics, including S1 and ABT‐737, induced endoplasmic reticulum (ER) stress and then activated MAPK/ERK pathway. The dual function of MAPK/ERK pathway in defining BH3 mimetics was illustrated; ERK1/2 activation leaded to Bcl‐2 transcriptional up‐regulation and sustained phosphorylation in naïve and acquired resistant SCLC cells. pBcl‐2 played a key role in creating resistance of S1 and ABT‐737 not only by sequestrating pro‐apoptotic proteins, but also sequestrating a positive feedback to promote ERK1/2 activation.Conclusions and Implications: These results provide significant novel insights into the molecular mechanisms for crosstalk between ER stress and endogenously apoptotic pathways in SCLC following BH3 mimetics treatment.Keywords
This publication has 46 references indexed in Scilit:
- Lung cancer and DNA repair genes: multilevel association analysis from the International Lung Cancer ConsortiumCarcinogenesis, 2012
- RETRACTED ARTICLE: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complexLeukemia, 2011
- Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stressNature Cell Biology, 2011
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1Blood, 2010
- A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignanciesCancer Chemotherapy and Pharmacology, 2010
- Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 bindingBlood, 2009
- Evidence for Involvement of ERK, PI3K, and RSK in Induction of Bcl-2 by ValproateJournal of Molecular Neuroscience, 2008
- Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung CancerCancer Research, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- BH3 mimetics to improve cancer therapy; mechanisms and examplesDrug Resistance Updates, 2007